Sriram Ryali
Director of Finance/CFO at CODEXIS, INC.
Net worth: 172 939 $ as of 30/04/2024
Sriram Ryali active positions
Companies | Position | Start | End |
---|---|---|---|
CODEXIS, INC. | Comptroller/Controller/Auditor | 23/01/2023 | - |
Director of Finance/CFO | 23/01/2023 | - |
Career history of Sriram Ryali
Former positions of Sriram Ryali
Companies | Position | Start | End |
---|---|---|---|
EIGER BIOPHARMACEUTICALS, INC. | Director of Finance/CFO | 03/12/2018 | 20/01/2023 |
Investor Relations Contact | 03/12/2018 | 20/01/2023 | |
Public Communications Contact | 03/12/2018 | 20/01/2023 | |
AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/12/2017 | 01/12/2018 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 01/01/2013 | 01/01/2015 |
Corporate Officer/Principal | 01/01/2011 | 01/01/2015 | |
JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/01/2015 | - |
Training of Sriram Ryali
University of California, Los Angeles | Undergraduate Degree |
UCLA Anderson School of Management | Masters Business Admin |
Statistics
International
United States | 7 |
Ireland | 2 |
Operational
Corporate Officer/Principal | 3 |
Director of Finance/CFO | 2 |
Investor Relations Contact | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Process Industries | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
JAZZ PHARMACEUTICALS PLC | Health Technology |
CODEXIS, INC. | Process Industries |
Private companies | 2 |
---|---|
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
- Stock Market
- Insiders
- Sriram Ryali
- Experience